ProQR Therapeutics (PRQR) Cash & Current Investments (2021 - 2025)
Historic Cash & Current Investments for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $159.7 million.
- ProQR Therapeutics' Cash & Current Investments rose 2477.45% to $159.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $159.7 million, marking a year-over-year increase of 2477.45%. This contributed to the annual value of $161.7 million for FY2024, which is 2570.42% up from last year.
- ProQR Therapeutics' Cash & Current Investments amounted to $159.7 million in Q4 2024, which was up 2477.45% from $128.0 million recorded in Q4 2023.
- In the past 5 years, ProQR Therapeutics' Cash & Current Investments registered a high of $219.1 million during Q4 2021, and its lowest value of $91.5 million during Q1 2021.
- Its 4-year average for Cash & Current Investments is $145.4 million, with a median of $140.4 million in 2023.
- Within the past 5 years, the most significant YoY rise in ProQR Therapeutics' Cash & Current Investments was 13040.81% (2022), while the steepest drop was 5527.8% (2022).
- Quarter analysis of 4 years shows ProQR Therapeutics' Cash & Current Investments stood at $219.1 million in 2021, then plummeted by 55.28% to $98.0 million in 2022, then soared by 30.59% to $128.0 million in 2023, then increased by 24.77% to $159.7 million in 2024.
- Its Cash & Current Investments was $159.7 million in Q4 2024, compared to $128.0 million in Q4 2023 and $131.5 million in Q3 2023.